An anonymous reader quotes a report from ScienceAlert: A genetically modified pig lung transplanted into a brain-dead human patient functioned for nine days in a new achievement that reveals both the promise and significant challenges of xenotransplantation. Over the course of the experiment, the patient showed increasing signs of organ rejection before scientists at the First Affiliated Hospital of Guangzhou Medical University in China terminated the experiment, allowing the recipient to pass away. It's the first time a pig lung has been transplanted into a human patient, demonstrating a significant step forward, and giving scientists new problems to solve as they develop this emerging medical technique further. [...]

The goal of the experiment was not to achieve a successful transplantation on the first try -- that would have been pretty incredible, but not a realistic expectation. Rather, the researchers wanted to observe how the patient's immune system responded to the transplanted organ. The patient was a 39-year-old man who was declared brain-dead by four separate clinical assessments after undergoing a brain hemorrhage. His family provided written informed consent for the experiment. The donor pig is what is known as a six-gene-edited pig, a Bama miniature pig with six CRISPR gene edits, housed in an isolated facility with rigorous disinfection protocols. These edits are all focused on minimizing the immune and inflammatory responses of the patient.

In a careful surgical procedure, the pig's left lung was placed into the patient's chest cavity, and connected to their airways, arteries, and veins. The paper does not explain the fate of the pig, but donor pigs do not typically survive the removal of a major organ. The patient was also treated with a number of immunosuppressants that the researchers adjusted according to changes observed in the patient's body over time. Initially, all seemed well, with none of the immediate signs of hyperacute rejection in the critical few hours following the procedure. However, by 24 hours after the transplant had taken place, severe swelling (edema) was observed, possibly as a result of blood flow being restored to the area of the transplant. Antibody-mediated rejection damaged the tissue further on days three and six of the experiment. The result of the damage was primary graft dysfunction, a type of severe lung injury occurring within 72 hours of a transplant, and the leading cause of death in lung transplant patients. Some recovery was taking place by day nine, but the experiment had run its course. The research has been published in Nature Medicine.

"For a few dozen people in the world, the downside of living with a rare immune condition comes with a surprising superpower — the ability to fight off all viruses..." notes an announcement from Columbia University. "At first, the condition only seemed to increase vulnerability to some bacterial infections. But as more patients were identified, its unexpected antiviral benefits became apparent." Columbia immunologist Dusan Bogunovic discovered the individuals' antiviral powers about 15 years ago, soon after he identified the genetic mutation that causes the condition... Bogunovic, a professor of pediatric immunology at Columbia University's Vagelos College of Physicians and Surgeons, soon learned that everyone with the mutation, which causes a deficiency in an immune regulator called ISG15, has mild, but persistent systemic inflammation... "In the back of my mind, I kept thinking that if we could produce this type of light immune activation in other people, we could protect them from just about any virus," Bogunovic says.

Today, Bogunovic is closing in on a therapeutic strategy that could provide that broad-spectrum protection against viruses and become an important weapon in next pandemic. In his latest study, published August 13 in Science Translational Medicine, Bogunovic and his team report that an experimental therapy they've developed temporarily gives recipients (hamsters and mice, so far) the same antiviral superpower as people with ISG15 deficiency. When administered prophylactically into the animals' lungs via a nasal drip, the therapy prevented viral replication of influenza and SARS-CoV-2 viruses and lessened disease severity. In cell culture, "we have yet to find a virus that can break through the therapy's defenses," Bogunovic says...

Bogunovic's therapeutic turns on production of 10 proteins that are primarily responsible for the broad antiviral protection. The current design resembles COVID mRNA vaccines but with a twist: Ten mRNAs encoding the 10 proteins are packaged inside a lipid nanoparticle. Once the nanoparticles are absorbed by the recipient's cells, the cells generate the ten host proteins to produce the antiviral protection. "We only generate a small amount of these ten proteins, for a very short time, and that leads to much less inflammation than what we see in ISG15-deficient individuals," Bogunovic says. "But that inflammation is enough to prevent antiviral diseases...."

"We believe the technology will work even if we don't know the identity of the virus," Bogunovic says. Importantly, the antiviral protection provided by the technology will not prevent people from developing their own immunological memory to the virus for longer-term protection.
"Our findings reinforce the power of research driven by curiosity without preconceived notions," Bogunovic says in the announcement. "We were not looking for an antiviral when we began studying our rare patients, but the studies have inspired the potential development of a universal antiviral for everyone."

More coverage from ScienceAlert.

Bill Gates is funding a $1 million competition to spur the use of AI to find innovative treatments for Alzheimer's disease, the latest effort to deploy the promising technology to find cures for humanity's toughest illnesses. From a report: The Alzheimer's Insights AI prize will be awarded to the team that comes up with the most original way to program AI-powered agents that are "capable of independent planning, reasoning, and action to accelerate breakthrough discoveries from existing Alzheimer's data."

 The winning tool will be released for free on the Alzheimer's Disease Data Initiative's cloud "workbench" to be used by scientists globally, the organisation said on Tuesday. The prize is being financed by Gates Ventures, the family office of the billionaire philanthropist and Microsoft co-founder.

"The U.S. is currently home to more than 18 million cancer survivors," reports the Wall Street Journal, "over 5% of the total population" (including those who are living with the disease).

Their article tells the story of Gwen Orilio, who was diagnosed with stage-four lung cancer at age 31. Ten years later she's still alive — and she still has metastatic cancer... Keeping her going is a string of new treatments that don't cure the disease but can buy months — even years — of time, with the hope that once one drug stops working a new one will come along. Orilio started on chemotherapy, and then switched to a new treatment, and then another, and another, and another... A small but growing population is living longer with incurable or advanced cancer, navigating the rest of their lives with a disease increasingly akin to a chronic illness. The trend, which started in breast cancer, has expanded to patients with melanoma, kidney cancer, lung cancer and others. The new drugs can add years to a life, even for some diagnoses like Orilio's that were once swift death sentences. They also put people in a state of limbo, living on a knife's edge waiting for the next scan to say a drug has stopped working and doctors need to find a new one. The wide range of survival times has made it more difficult for cancer doctors to predict how much time a patient might have left. For most, the options eventually run out....

More than 690,000 people were projected to be living with stage-four or metastatic disease of the six most common cancers — melanoma, breast, bladder, colorectal, prostate or lung cancer — in 2025, according to a 2022 report from the National Cancer Institute. That's an increase from 623,000 in 2018 and a significant rise since 1990, the report found... Nearly 30% of survivors diagnosed with metastatic melanoma and 20% of those diagnosed with metastatic colorectal or breast cancer had been living with their disease for a decade or more, the NCI paper estimated... Even for lung cancer, the biggest U.S. cancer killer, the five-year relative survival rate for advanced disease has inched up, from 3.7% for patients diagnosed in 2004 to 9.2% for patients diagnosed in 2017, federal data show. The overall lung cancer survival rate has risen by 26% in the past five years, according to the American Lung Association, as declining cigarette use, screening and new drugs have driven down deaths.

The expanding number of therapies that target a cancer's mutations or boost the immune system are improving the outlook for several cancers. In breast cancer, treatment for metastatic disease accounted for 29% of the drop in deaths between 1975 and 2019, according to one 2024 estimate, with screening and treatment for early-stage disease accounting for the rest.
The number of American cancer survivors (or those living with cancer) is expected to grow to 26 million by 2040," the article points out.

alternative_right shares a report from Phys.org: Take note of the name: ReHMGB1. A new study pinpoints this protein as being able to spread the wear and tear that comes with time as it quietly travels through the bloodstream. This adds significantly to our understanding of aging. The researchers were able to identify ReHMGB1 as a critical messenger passing on the senescence signal by analyzing different types of human cells grown in the lab and conducting a variety of tests on mice. When ReHMGB1 transmission was blocked in mice with muscle injuries, muscle regeneration happened more quickly, while the animals showed improved physical performance, fewer signs of cellular aging, and reduced systemic inflammation. The findings have been published in the journal Metabolism.

An anonymous reader quotes a report from ScientificAmerican: After a brain stem stroke left him almost entirely paralyzed in the 1990s, French journalist Jean-Dominique Bauby wrote a book about his experiences -- letter by letter, blinking his left eye in response to a helper who repeatedly recited the alphabet. Today people with similar conditions often have far more communication options. Some devices, for example, track eye movements or other small muscle twitches to let users select words from a screen. And on the cutting edge of this field, neuroscientists have more recently developed brain implants that can turn neural signals directly into whole words. These brain-computer interfaces (BCIs) largely require users to physically attempt to speak, however -- and that can be a slow and tiring process. But now a new development in neural prosthetics changes that, allowing users to communicate by simply thinking what they want to say.

The new system relies on much of the same technology as the more common "attempted speech" devices. Both use sensors implanted in a part of the brain called the motor cortex, which sends motion commands to the vocal tract. The brain activation detected by these sensors is then fed into a machine-learning model to interpret which brain signals correspond to which sounds for an individual user. It then uses those data to predict which word the user is attempting to say. But the motor cortex doesn't only light up when we attempt to speak; it's also involved, to a lesser extent, in imagined speech. The researchers took advantage of this to develop their "inner speech" decoding device and published the results on Thursday in Cell. The team studied three people with amyotrophic lateral sclerosis (ALS) and one with a brain stem stroke, all of whom had previously had the sensors implanted. Using this new "inner speech" system, the participants needed only to think a sentence they wanted to say and it would appear on a screen in real time. While previous inner speech decoders were limited to only a handful of words, the new device allowed participants to draw from a dictionary of 125,000 words. To help keep private thoughts private, the researchers implemented a code phrase "chitty chitty bang bang" that participants could use to prompt the BCI to start or stop transcribing.

China launched the World Humanoid Robot Games on Friday. The three-day event will see 280 teams from 16 countries compete in football, track and field, and table tennis alongside robot-specific challenges including medicine sorting and cleaning services. The event also features 192 university teams and 88 private enterprise teams from the U.S., Germany, Brazil and other nations as well as Chinese companies Unitree and Fourier among participants.

Beijing municipal government serves as an organizing body. The Chinese robotics sector has received over $20 billion in government subsidies in the past year with Beijing planning a one trillion yuan ($137 billion) fund for AI and robotics startups. A previous Beijing humanoid robot marathon saw several competitors emit smoke and fail to complete the course.

An anonymous reader New Atlas: An engineered protein that acts like a molecular sponge has the potential to change how carbon monoxide poisoning is treated, chasing down CO molecules in the bloodstream and helping the body flush them out in just minutes, without the risk of short- or long-term health issues that come with the current frontline treatment, pure oxygen. Researchers at the University of Maryland School of Medicine (UMSOM) were focused on a natural protein known as RcoM, found in the bacterium Paraburkholderia xenovorans. In bacteria, RcoM detects trace amounts of CO in the environment, so the engineers believed this could be harnessed to scavenge for CO molecules attached to red blood cells instead.

The re-engineered protein is the basis of the therapy they call RcoM-HBD-CCC. While it's not exactly a catchy name, it possesses somewhat of a superpower when it comes to cleaning out CO. It selectively binds tightly to the poisonous CO molecules, while ignoring oxygen (O2) and other critical chemical compounds, such as blood-pressure-regulating nitric oxide (NO), in the body. [...] In mouse models, RcoM-HBD-CCC therapy was able to clear CO from the blood in minutes, with it safely flushed out of the body through urine. The engineered antidote acts like a sponge, seeking out and soaking up CO attached to red blood cells. In mice, half the CO in the bloodstream was cleared out in less than a minute, freeing the hemoglobin on the cells to once again start carrying O2.

Importantly, other experimental scavenger hemoproteins haven't been able to selectively target CO, and as a result also bind to NO – so infusions of such hemoproteins can lead to a reduction of NO in the blood, tightening blood vessels and spiking blood pressure. In the study, RcoM-HBD-CCC showed it didn't have this affinity with the vital molecule. "Unlike other protein-based treatments, we found the compound caused only minimal changes in blood pressure, which was an exciting finding and raised the potential for this new molecule to have clinical applications," said study corresponding author Dr Mark T. Gladwin, Dean of UMSOM. "This has the potential to become a rapid, intravenous antidote for carbon monoxide that could be given in the emergency department or even in the field by first-responders." The study was published in the journal Proceedings of the National Academy of Sciences (PNAS).

An anonymous reader quotes a report from the BBC: Experts at the University of Edinburgh carried out a post-mortem brain examination on 25 cats which had symptoms of dementia in life, including confusion, sleep disruption and an increase in vocalization. They found a build-up of amyloid-beta, a toxic protein and one of the defining features of Alzheimer's disease. The discovery has been hailed as a "perfect natural model for Alzheimer's" by scientists who believe it will help them explore new treatments for humans.

Dr Robert McGeachan, study lead from the University of Edinburgh's Royal (Dick) School of Veterinary Studies, said: "Dementia is a devastating disease -- whether it affects humans, cats, or dogs. Our findings highlight the striking similarities between feline dementia and Alzheimer's disease in people. This opens the door to exploring whether promising new treatments for human Alzheimer's disease could also help our ageing pets." [...]

Previously, researchers have studied genetically-modified rodents, although the species does not naturally suffer from dementia. "Because cats naturally develop these brain changes, they may also offer a more accurate model of the disease than traditional laboratory animals, ultimately benefiting both species and their caregivers," Dr McGeachan said. [...] Prof Danielle Gunn-Moore, an expert in feline medicine at the vet school, said the discovery could also help to understand and manage feline dementia. The findings have been published in the European Journal of Neuroscience.

An anonymous reader quotes a report from Ars Technica: In recent months, the AI industry has started moving toward so-called simulated reasoning models that use a "chain of thought" process to work through tricky problems in multiple logical steps. At the same time, recent research has cast doubt on whether those models have even a basic understanding of general logical concepts or an accurate grasp of their own "thought process." Similar research shows that these "reasoning" models can often produce incoherent, logically unsound answers when questions include irrelevant clauses or deviate even slightly from common templates found in their training data.

In a recent pre-print paper, researchers from the University of Arizona summarize this existing work as "suggest[ing] that LLMs are not principled reasoners but rather sophisticated simulators of reasoning-like text." To pull on that thread, the researchers created a carefully controlled LLM environment in an attempt to measure just how well chain-of-thought reasoning works when presented with "out of domain" logical problems that don't match the specific logical patterns found in their training data. The results suggest that the seemingly large performance leaps made by chain-of-thought models are "largely a brittle mirage" that "become[s] fragile and prone to failure even under moderate distribution shifts," the researchers write. "Rather than demonstrating a true understanding of text, CoT reasoning under task transformations appears to reflect a replication of patterns learned during training." [...]

Rather than showing the capability for generalized logical inference, these chain-of-thought models are "a sophisticated form of structured pattern matching" that "degrades significantly" when pushed even slightly outside of its training distribution, the researchers write. Further, the ability of these models to generate "fluent nonsense" creates "a false aura of dependability" that does not stand up to a careful audit. As such, the researchers warn heavily against "equating [chain-of-thought]-style output with human thinking" especially in "high-stakes domains like medicine, finance, or legal analysis." Current tests and benchmarks should prioritize tasks that fall outside of any training set to probe for these kinds of errors, while future models will need to move beyond "surface-level pattern recognition to exhibit deeper inferential competence," they write.

An anonymous reader quotes a report from The Guardian: They are supposed to monitor you throughout the working day and help make sure that life is not getting on top of you. But a study has concluded that smartwatches cannot accurately measure your stress levels -- and may think you are overworked when really you are just excited. Researchers found almost no relationship between the stress levels reported by the smartwatch and the levels that participants said they experienced. However, recorded fatigue levels had a very slight association with the smartwatch data, while sleep had a stronger correlation.

Eiko Fried, an author of the study, said the correlation between the smartwatch and self-reported stress scores was "basically zero." He added: "This is no surprise to us given that the watch measures heart rate and heart rate doesn't have that much to do with the emotion you're experiencing -- it also goes up for sexual arousal or joyful experiences." He noted that his Garmin had previously told him he was stressed when he was working out in the gym and when excitedly talking to a friend he had not seen for a while at a wedding. "The findings raise important questions about what wearable data can or can't tell us about mental states," said Fried. "Be careful and don't live by your smartwatch -- these are consumer devices, not medical devices." The research has been published in the Journal of Psychopathology and Clinical Science.

An anonymous reader quotes a report from New Scientist: People withAlzheimer's disease have lower levels of lithium in their brains, and giving lithium to mice with symptoms of the condition reverses cognitive decline. Together, the findings suggest that lithium deficiency could be a driver of Alzheimer's disease and that low-dose lithium medications could help treat it. [...] [Bruce Yanknerat Harvard University] and his colleagues analyzed levels of 27 metals in the brains of 285 people after they died, 94 of whom were diagnosed with Alzheimer's disease and 58 of whom had mild cognitive impairment, a precursor of the condition. The other participants showed no signs of cognitive decline at the time of their death.

Lithium levels in the prefrontal cortex -- a brain region crucial for memory and decision-making -- were about 36 percent lower, on average, in people with Alzheimer's disease than in those without any cognitive decline. For those with mild cognitive impairment, lithium levels were about 23 percent lower. "We suspect that's due to a number of environmental factors: dietary intake, genetics and so forth," says Yankner. Yet there seemed to be another reason, too. In those with Alzheimer's disease, clumps of proteins called amyloid plaques contained nearly three times the amount of lithium as plaque-free regions of their brain. "Lithium becomes sequestered in these plaques," says Yankner. "We have two things going on. There is impaired uptake of lithium [in the brain] very early on and then, as the disease progresses, the lithium that is in the brain is further diminished by being bound to amyloid."

To understand how this influences cognition, the team genetically engineered 22 mice to develop Alzheimer's-like symptoms and reduced their lithium intake by 92 percent. After about eight months, the animals performed significantly worse on multiple memory tests compared with 16 mice on a standard diet. It took lithium-deficient mice around 10 seconds longer to find a hidden platform in a water maze, for example, even after six days of training. Their brains also contained nearly two and a half times as many amyloid plaques. Genetic analysis of brain cells from the lithium-deficient mice showed increased activity in genes related to neurodegeneration and Alzheimer's. They also had more brain inflammation and their immune cells were less able to clear away amyloid plaques, changes also seen in people with Alzheimer's disease.

The team then screened different lithium compounds for their ability to bind to amyloid and found that lithium orotate -- a naturally occurring compound in the body formed by combining lithium with orotic acid -- appeared to be the least likely to get trapped within plaques. Nine months of treatment with this compound significantly reduced plaques in mice with Alzheimer's-like symptoms, and they also performed as well on memory tests as normal mice. These results suggest lithium orotate could be a promising treatment for Alzheimer's. The findings have been published in the journal Nature.

A new paper from Bangor University outlines the "bizarre phenomenon" known as the transparency paradox: that transparency is needed to foster public trust in science, but being transparent about science, medicine and government can also reduce trust. The paper argues that while openness in science is intended to build trust, it can backfire when revealing uncomfortable truths. Philosopher Byron Hyde and author of the study suggests that public trust could be improved not by sugarcoating reality, but by educating people to expect imperfection and understand how science actually works. Phys.org reports: The study revealed that, while transparency about good news increases trust, transparency about bad news, such as conflicts of interest or failed experiments, decreases it. Therefore, one possible solution to the paradox, and a way to increase public trust, is to lie (which Hyde points out is unethical and ultimately unsustainable), by for example making sure bad news is hidden and that there is always only good news to report.

Instead, he suggests that a better way forward would be to tackle the root cause of the problem, which he argues is the public overidealising science. People still overwhelmingly believe in the 'storybook image' of a scientist who makes no mistakes, which creates unrealistic expectations. Hyde is calling for a renewed effort to teach the public about scientific norms, which would be done through science education and communication to eliminate the "naive" view of science as infallible. "... most people know that global temperatures are rising, but very few people know how we know that," says Hyde. "Not enough people know that science 'infers to the best explanation' and doesn't definitively 'prove' anything. Too many people think that scientists should be free from biases or conflicts of interest when, in fact, neither of these are possible. If we want the public to trust science to the extent that it's trustworthy, we need to make sure they understand it first."

The study has been published in the journal Theory and Society.

fjo3 shares a report from the Associated Press: The Trump administration announced it is launching a new program that will allow Americans to share personal health data and medical records across health systems and apps run by private tech companies, promising that will make it easier to access health records and monitor wellness. More than 60 companies, including major tech companies like Google, Amazon and Apple as well as health care giants like UnitedHealth Group and CVS Health, have agreed to share patient data in the system. The initiative will focus on diabetes and weight management, conversational artificial intelligence that helps patients, and digital tools such as QR codes and apps that register patients for check-ins or track medications.

Officials at the Centers for Medicare and Medicaid Services, who will be in charge of maintaining the system, have said patients will need to opt in for the sharing of their medical records and data, which will be kept secure. Those officials said patients will benefit from a system that lets them quickly call up their own records without the hallmark difficulties, such as requiring the use of fax machines to share documents, that have prevented them from doing so in the past.

Popular weight loss and fitness subscription service Noom, which has signed onto the initiative, will be able to pull medical records after the system's expected launch early next year. That might include labs or medical tests that the app could use to develop an AI-driven analysis of what might help users lose weight, CEO Geoff Cook told The Associated Press. Apps and health systems will also have access to their competitors' information, too. Noom would be able to access a person's data from Apple Health, for example. "Right now you have a lot of siloed data," Cook said.

The world's "oldest baby" has been born in the US from an embryo that was frozen in 1994, it has been reported. The Guardian: Thaddeus Daniel Pierce was born on 26 July in Ohio to Lindsey and Tim Pierce, using an "adopted" embryo from Linda Archerd, 62, from more than 30 years ago.

In the early 1990s, Archerd and her then husband decided to try in vitro fertilisation (IVF) after struggling to become pregnant. In 1994 four embryos resulted: one was transferred to Archerd and resulted in the birth of a daughter, who is now 30 and mother to a 10-year-old. The other embryos were cryopreserved and stored.

"We didn't go into it thinking we would break any records," Lindsey told the MIT Technology Review, which first reported the story. "We just wanted to have a baby."

sciencehabit shares a report from Science.org: Peacocks have a secret hidden in their brightly colored tail feathers: tiny reflective structures that can amplify light into a laser beam. After dyeing the feathers and energizing them with an external light source, researchers discovered they emitted narrow beams of yellow-green laser light. They say the study, published this month in Scientific Reports, offers the first example of a laser cavity in the animal kingdom. [...]

Scientists have long known that peacock feathers also exhibit "structural color" -- nature's pigment-free way to create dazzling hues. Ordered microstructures within the feathers reflect light at specific frequencies, leading to their vivid blues and greens and iridescence. But Florida Polytechnic University physicist Nathan Dawson and his colleagues wanted to go a step further and see whether those microstructures could also function as a laser cavity. After staining the feathers with a common dye and pumping them with soft pulses of light, they used laboratory instruments to detect beams of yellow-green laser light that were too faint to see with the naked eye. They emerged from the feathers' eyespots, at two distinct wavelengths. Surprisingly, differently colored parts of the eyespots emitted the same wavelengths of laser light, even though each region would presumably vary in its microstructure.

Just because peacock feathers emit laser light doesn't mean the birds are somehow using this emission. But there are still ramifications, Dawson says. He suggests that looking for laser light in biomaterials could help identify arrays of regular microstructures within them. In medicine, for example, certain foreign objects -- viruses with distinct geometric shapes, perhaps -- could be classified and identified based on their ability to be lasers, he says. The work also demonstrates how biological materials could one day yield lasers that could be put safely into the human body to emit light for biosensing, medical imaging, and therapeutics. "I always like to think that for many technological achievements that benefit humans," Dawson says, "some organism somewhere has already developed it through some evolutionary process."

Promising Phase 3 trial results from Apnimed suggest a potential game-changing oral pill for sleep apnea could offer a simpler, more tolerable alternative for keeping airways open during sleep. The New York Times reports: For decades, the primary treatment for sleep apnea has been continuous positive airway pressure (or CPAP). Before bed, those with the condition put on a face mask that is connected to a CPAP machine, which keeps the airway open by forcing air into it. The machines are effective, but many find them so noisy, cumbersome or uncomfortable that they end up abandoning them. Now, a more appealing option may be on the way, according to a news release from Apnimed, a pharmaceutical company focused on treating sleep apnea. On Wednesday, the company announced a second round of positive Phase 3 clinical trial results for a first-of-its-kind oral pill that can be taken just before bedtime to help keep a person's airway open.

The full results have not yet been released, or published in a peer-reviewed journal. But the findings build on past, similarly positive conclusions from trials and studies. Sleep experts say that what they're seeing in reports so far makes them think the pill could be a game changer. Dr. Phyllis Zee, a sleep doctor and researcher at Northwestern Medicine who was not involved with the trial, said that if approved, the drug could transform the lives of many. That includes not only those who can't tolerate CPAP machines, but also those who can't -- or prefer not to -- use other interventions, such as other types of oral devices or weight loss medications. (Excess weight is a risk factor for sleep apnea.)

Scientists at the University of Maryland are developing ErythroMer, a freeze-dried artificial blood substitute made from hemoglobin encased in fat bubbles, designed to be shelf-stable for years and reconstituted with water in emergencies. With promising animal trial results and significant funding from the Department of Defense, the team aims to begin human testing within two years. NPR reports: "The No. 1 cause of preventable death on the battlefield is hemorrhage still today," says Col. Jeremy Pamplin, the project manager at the Defense Advanced Research Projects Agency. "That's a real problem for the military and for the civilian world." [Dr. Allan Doctor, a scientist at the University of Maryland working to develop the artificial blood substitute] is optimistic his team may be on the brink of solving that problem with ... ErythroMer. Doctor co-founded KaloCyte to develop the blood and serves on the board and as the firm's chief scientific officer.

"We've been able to successfully recapitulate all the functions of blood that are important for a resuscitation in a system that can be stored for years at ambient temperature and be used at the scene of an accident," he says. [...] Doctor's team has tested their artificial blood on hundreds of rabbits and so far it looks safe and effective. "It would change the way that we could take care of people who are bleeding outside of hospitals," Doctor says. "It'd be transformative." [...]

While the results so far seem like cause for optimism, Doctor says he still needs to prove to the Food and Drug Administration that his artificial blood would be safe and effective for people. But he hopes to start testing it in humans within two years. A Japanese team is already testing a similar synthetic blood in people. "I'm very hopeful," Doctor says. While promising, some experts remain cautious, noting that past attempts at artificial blood ultimately proved unsafe. "I think it's a reasonable approach," says Tim Estep, a scientist at Chart Biotech Consulting who consults with companies developing artificial blood. "But because this field has been so challenging, the proof will be in the clinical trials," he adds. "While I'm overall optimistic, placing a bet on any one technology right now is overall difficult."

A Chinese inventor with no medical training is charging cancer patients $20,000 to inject highly concentrated chlorine dioxide -- a toxic bleach solution -- directly into their tumors, and is working with a former pharmaceutical executive to bring the unproven treatment to the United States, Wired reports.

Xuewu Liu uses injections containing 20,000 parts per million of chlorine dioxide, significantly higher than the 3,000 ppm concentrations typically found in oral bleach solutions peddled by pseudoscience promoters. One patient told WIRED her tumor grew faster after Liu's injections and suspects the treatment caused her cancer to spread to her skin.

An anonymous reader quotes a report from The Guardian: In addition to sanitation, medicine, education, wine, public order, irrigation, roads, a freshwater system and public health, the Romans also produced a lot of inscriptions. Making sense of the ancient texts can be a slog for scholars, but a new artificial intelligence tool from Google DeepMind aims to ease the process. Named Aeneas after the mythical Trojan hero, the program predicts where and when inscriptions were made and makes suggestions where words are missing. Historians who put the program through its paces said it transformed their work by helping them identify similar inscriptions to those they were studying, a crucial step for setting the texts in context, and proposing words to fill the inevitable gaps in worn and damaged artefacts. [...]

The Google team led by Yannis Assael worked with historians to create an AI tool that would aid the research process. The program is trained on an enormous database of nearly 200,000 known inscriptions, amounting to 16m characters. Aeneas takes text, and in some cases images, from the inscription being studied and draws on its training to build a list of related inscriptions from 7th century BC to 8th century BC. Rather than merely searching for similar words, the AI identifies and links inscriptions through deeper historical connections. Having trained on the rich collection of inscriptions, the AI can assign study texts to one of 62 Roman provinces and estimate when it was written to within 13 years. It also provides potential words to fill in any gaps, though this has only been tested on known inscriptions where text is blocked out.

In a test run, researchers set Aeneas loose on a vast inscription carved into monuments around the Roman empire. The self-congratulatory Res Gestae Divi Augusti describes the life achievements of the first Roman emperor, Augustus. Aeneas came up with two potential dates for the work, either the first decade BC or between 10 and 20AD. The hedging echoes the debate among scholars who argue over the same dates. In another test, Aeneas analysed inscriptions on a votive altar from Mogontiacum, now Mainz in Germany, and revealed through subtle linguistic similarities how it had been influenced by an older votive altar in the region. "Those were jaw-dropping moments for us," said [Dr Thea Sommerschield, a historian at the University of Nottingham who developed Aeneas with the tech firm]. Details are published in Nature and Aeneas is available to researchers online.